Argobio

Argobio is a Paris-based biotech start-up studio launched in 2021 with €50 million in committed capital from leading investors. It identifies and incubates early-stage therapeutic projects sourced from top European academic institutions—focusing on rare diseases, neurology, oncology, and immunology—and builds them into independent biotech companies. Its model provides operational support and funding through preclinical development up to Series A financing. Notable recent spinouts include Enodia Therapeutics (targeted protein degradation using AI-designed small molecules) and Inverna Therapeutics (RNA splicing modulation for genetic diseases).